

Amendments to the Specification

Please amend the Abstract of this application as following:

--Methods ~~are disclosed~~ for the treatment and prevention of disorders and conditions using a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound are disclosed. Disorders and conditions that can be treated or prevented include ~~such as, but are not limited to:~~ eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.

Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.--